577 related articles for article (PubMed ID: 25660156)
41. Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment.
Huang CW; Yeh YS; Ma CJ; Tsai HL; Chen CW; Huang MY; Lu CY; Wu JY; Wang JY
Chemotherapy; 2017; 62(1):80-84. PubMed ID: 27654129
[TBL] [Abstract][Full Text] [Related]
42. [Bevacizumab in combination with mFOLFOX6 or FOLFIRI for previously treated metastatic colorectal cancer].
Koyama M; Murata A; Kimura Y; Sakamoto Y; Morohashi H; Kimura N; Gasa F; Sato J; Terui K; Awatsu A; Hakamada K
Gan To Kagaku Ryoho; 2010 Jun; 37(6):1069-73. PubMed ID: 20567110
[TBL] [Abstract][Full Text] [Related]
43. FOLFOXIRI Regimen for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
Leal F; Ferreira FP; Sasse AD
Clin Colorectal Cancer; 2017 Dec; 16(4):405-409.e2. PubMed ID: 28433602
[TBL] [Abstract][Full Text] [Related]
44. How should BRAF V600E-mutated colorectal cancer be treated?
Kopetz S
Clin Adv Hematol Oncol; 2018 May; 16(5):333-335. PubMed ID: 29851929
[No Abstract] [Full Text] [Related]
45. Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
Del Rio M; Mollevi C; Bibeau F; Vie N; Selves J; Emile JF; Roger P; Gongora C; Robert J; Tubiana-Mathieu N; Ychou M; Martineau P
Eur J Cancer; 2017 May; 76():68-75. PubMed ID: 28284171
[TBL] [Abstract][Full Text] [Related]
46. Perforating dermatosis in a patient receiving bevacizumab.
Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
[No Abstract] [Full Text] [Related]
47. [Safety and efficacy of FOLFOX and FOLFIRI in elderly patients with colorectal cancer].
Mishima H; Ikenaga M; Yasui M
Nihon Rinsho; 2011 Apr; 69 Suppl 3():554-8. PubMed ID: 22214022
[No Abstract] [Full Text] [Related]
48. Body surface area-based dosing of 5-fluoruracil results in extensive interindividual variability in 5-fluorouracil exposure in colorectal cancer patients on FOLFOX regimens.
Saam J; Critchfield GC; Hamilton SA; Roa BB; Wenstrup RJ; Kaldate RR
Clin Colorectal Cancer; 2011 Sep; 10(3):203-6. PubMed ID: 21855044
[No Abstract] [Full Text] [Related]
49. Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
Venook AP; Blanke CD; Niedzwiecki D; Lenz HJ; Taylor JR; Hollis DR; Sutherland S; Goldberg RM
Clin Colorectal Cancer; 2005 Nov; 5(4):292-4. PubMed ID: 16356309
[No Abstract] [Full Text] [Related]
50. The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer.
Grothey E; Chu E
Clin Colorectal Cancer; 2007 Sep; 6(9):621-4. PubMed ID: 17945033
[No Abstract] [Full Text] [Related]
51. Adjuvant treatment of colon cancer: what is next?
Van Loon K; Venook AP
Curr Opin Oncol; 2011 Jul; 23(4):403-9. PubMed ID: 21537178
[TBL] [Abstract][Full Text] [Related]
52. FOLFOXIRI plus biologics in advanced colorectal cancer.
García-Alfonso P; Torres G; García G; Gallego I; Ortega L; Sandoval C; Muñoz A; Lloansí A
Expert Opin Biol Ther; 2019 May; 19(5):411-422. PubMed ID: 30887844
[TBL] [Abstract][Full Text] [Related]
53. FOLFIRI+bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9--FFCD 0802).
Aparicio T; Linot B; Le Malicot K; Bouché O; Boige V; François E; Ghiringhelli F; Legoux JL; Ben Abdelghani M; Phelip JM; Faroux R; Dahan L; Taieb J; Bedenne L
Dig Liver Dis; 2015 Apr; 47(4):271-2. PubMed ID: 25677925
[No Abstract] [Full Text] [Related]
54. First description of an uterine perforation potentially imputable to treatment with bevacizumab.
Uguen T; Leconte B; Desgrippes R; Tchoundeu B; Bretagne JF; Manfredi S
Acta Oncol; 2012 Nov; 51(8):1102-4. PubMed ID: 23020310
[No Abstract] [Full Text] [Related]
55. Always look at the bright side of drugs?
Nygren P
Acta Oncol; 2015 Feb; 54(2):145-7. PubMed ID: 25608927
[No Abstract] [Full Text] [Related]
56. Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?
Loupakis F; Falcone A
Nat Rev Clin Oncol; 2010 Apr; 7(4):190-1. PubMed ID: 20354542
[TBL] [Abstract][Full Text] [Related]
57. An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.
Rizzo A; Palloni A; Frega G; Abbati F; De Lorenzo S; Brocchi S; Brandi G
Anticancer Drugs; 2019 Apr; 30(4):428-430. PubMed ID: 30875350
[TBL] [Abstract][Full Text] [Related]
58. Complete Metabolic Response Assessed by FDG PET/CT to FOLFOXIRI-Bevacizumab in First-Line Treatment of BRAFV600E Mutated Metastatic Colorectal Cancer.
Amrane K; le Pennec R; Schick U; Metges JP; Abgral R
Clin Nucl Med; 2020 Sep; 45(9):707-708. PubMed ID: 32657876
[TBL] [Abstract][Full Text] [Related]
59. Correlation between response to chemotherapy with concomitant bevacizumab for hepatic metastasis of colorectal cancer and degree of enhancement using contrast-enhanced computed tomography.
Osawa G; Yoshimatsu K; Yokomizo H; Okayama S; Sagawa M; Naritaka Y
Cancer Chemother Pharmacol; 2013 Jul; 72(1):209-15. PubMed ID: 23670642
[TBL] [Abstract][Full Text] [Related]
60. Challenge of primary tumor management in patients with stage IV colorectal cancer.
Chang GJ
J Clin Oncol; 2012 Sep; 30(26):3165-6. PubMed ID: 22869881
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
